Ovarian Toxicity Assessment

HIGHLIGHTS

• Despite its importance, ovarian toxicity is rarely assessed in clinical trials
• It is important to understand the impact of new treatment options on fertility and ovarian function
• The main barrier to the assessment of ovarian toxicity was lack of prioritisation
• Other barriers are resources and uncertainty regarding how to assess ovarian toxicity
• Clinical guidelines and and stronger advocacy from key stakeholders, including regulators may facilitate more frequent inclusion in future trials

Access the Full Paper here.